The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
 
Jay Oza
No Relationships to Disclose
 
Shing Mirn Lee
Consulting or Advisory Role - PTC Therapeutics
Research Funding - AstraZeneca (Inst); Karyopharm Therapeutics (Inst); Merck (Inst)
 
Mia C. Weiss
No Relationships to Disclose
 
Brittany L Siontis
Consulting or Advisory Role - Deciphera (Inst)
Research Funding - Deciphera (Inst)
 
Benjamin C. Powers
No Relationships to Disclose
 
Warren Allen Chow
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - Advenchen Laboratories; Via Oncology
 
Wendy Magana
No Relationships to Disclose
 
Tahir Sheikh
No Relationships to Disclose
 
Richard Piekarz
No Relationships to Disclose
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; JOHNSON AND JOHNSON COM; Merck; Pfizer
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; Ellipses Pharma; Epizyme; Fortress Biotech; Gencirq; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Array BioPharma; Daiichi Sankyo; Epizyme; Epizyme; Iovance Biotherapeutics; PTC Therapeutics; PureTech
 
Matthew Ingham
Consulting or Advisory Role - Apexigen; Daiichi Sankyo; Xencor
Research Funding - Apexigen (Inst); Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech